About the SPORE
The Mayo Clinic Multiple Myeloma SPORE aims to improve treatment for patients with multiple myeloma and to advance understanding of the mechanisms of disease initiation, progression and relapse.
The Multiple Myeloma SPORE includes four major translational research projects, core resources, the Developmental Research Program and the Career Enhancement Program.The Multiple Myeloma SPORE is part of the Hematologic Malignancies Program, which conducts research about cancers of the blood and bone marrow.
The Multiple Myeloma SPORE uses an interdisciplinary approach to achieve its research objectives.
The SPORE brings together researchers with expertise in basic, applied and clinical science from all three Mayo Clinic campuses in Arizona, Florida and Minnesota. Together, these investigators have published more than 1,500 articles related to multiple myeloma and are recognized leaders in the field.
Mayo Clinic SPORE investigators work together as a team and collaborate with investigators from multiple myeloma SPOREs at other institutions to improve outcomes for patients.
Renowned journalist and Mayo Clinic Trustee Tom Brokaw serves as the patient advocate to the SPORE to represent the interests of patients with multiple myeloma and increase awareness of and support for multiple myeloma research.
The Mayo Clinic Multiple Myeloma SPORE is funded by the National Cancer Institute (NCI), which awarded Mayo Clinic a five-year, $11.5 million grant in September 2015. A SPORE, or Specialized Program of Research Excellence, is a cornerstone of the NCI's efforts to promote collaborative, interdisciplinary translational cancer research.
The principal investigator for the Mayo Clinic Multiple Myeloma SPORE is Leif Bergsagel, M.D.